{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:14:14Z","timestamp":1781889254125,"version":"3.54.5"},"reference-count":36,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"unspecified","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"University of Occupational & Environmental Health, Japan for Advanced Research","award":["#19K17919"],"award-info":[{"award-number":["#19K17919"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,1,5]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the 2-year clinical effectiveness of the four globally approved Janus kinase inhibitors (JAKis; tofacitinib (TOF), baricitinib (BAR), upadacitinib (UPA) and filgotinib (FIL)) in patients with rheumatoid arthritis (RA) in real-world settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study used data from FIRST registry, a multicentre registry of patients with RA. The primary endpoint was the change in Clinical Disease Activity Index (CDAI) score at year 2. Secondary endpoints included changes in individual CDAI components, patient-reported outcomes (PROs) and reasons for JAKi discontinuation. Multivariable mixed-effects models adjusted for baseline characteristics were used to compare the four JAKis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 607 treatment courses with JAKis (TOF: 159, BAR: 262, UPA: 122, FIL: 64) were included. Baseline characteristics differed notably among treatment groups: UPA and FIL were frequently used as the second-line JAKis for older patients with comorbidities. The 2-year overall retention rate was 78%. The most common reason for discontinuation was insufficient effectiveness, with 6.5\/100 person-years (py), followed by adverse events of 4.2\/100 py. As-observed analysis demonstrated the slower improvement in the UPA and FIL groups. However, multivariable analysis revealed no significant differences in CDAI or PROs. The UPA group demonstrated greater improvement in two CDAI components: tender joint count and evaluator\u2019s global assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This real-world study found no clinically meaningful differences in 2-year effectiveness among four JAKis, although the study was not powerful enough to detect differences in safety. Further long-term, real-world data are needed to evaluate the safety of these agents and refine their risk-benefit profiles.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-006503","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T19:15:39Z","timestamp":1768590939000},"page":"e006503","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of tofacitinib, baricitinib, upadacitinib and filgotinib: a 2-year observational study from FIRST registry"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4003-8842","authenticated-orcid":false,"given":"Koshiro","family":"Sonomoto","sequence":"first","affiliation":[{"name":"Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"},{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2209-8454","authenticated-orcid":false,"given":"Shingo","family":"Nakayamada","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6220-1233","authenticated-orcid":false,"given":"Hidenori","family":"Sakai","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0212-172X","authenticated-orcid":false,"given":"Masanobu","family":"Ueno","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3022-1317","authenticated-orcid":false,"given":"Hiroaki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"},{"name":"Department of Medical Informatics and Management, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-1091","authenticated-orcid":false,"given":"Atsushi","family":"Nagayasu","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0266-2342","authenticated-orcid":false,"given":"Takafumi","family":"Aritomi","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2777-743X","authenticated-orcid":false,"given":"Makoto","family":"Okawara","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine and Community Health, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3008-4615","authenticated-orcid":false,"given":"Akinori","family":"Nakata","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine and Community Health, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Molecular Targeted Therapeutics, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"2026011611152410000_12.1.e006503.1","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026011611152410000_12.1.e006503.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"2026011611152410000_12.1.e006503.3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/mr\/roaf006","article-title":"2024 Update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis: Secondary publication","volume":"35","author":"Harigai","year":"2025","journal-title":"Mod Rheumatol"},{"key":"2026011611152410000_12.1.e006503.4","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ard.2025.01.032","article-title":"Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update","volume":"84","author":"Nash","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026011611152410000_12.1.e006503.5","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1387585","article-title":"Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: a systematic review and network meta-analysis of randomized controlled trials","volume":"15","author":"Cai","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026011611152410000_12.1.e006503.6","doi-asserted-by":"crossref","DOI":"10.3390\/ph18020178","article-title":"Comparative Efficacy and Safety of JAK Inhibitors in the Management of Rheumatoid Arthritis: A Network Meta-Analysis","volume":"18","author":"Almoallim","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026011611152410000_12.1.e006503.7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40744-025-00757-7","article-title":"Filgotinib Radiographic and Clinical Efficacy Versus Other JAK Inhibitors and Adalimumab in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate: A Systematic Review and Network Meta-Analysis","volume":"12","author":"Tanaka","year":"2025","journal-title":"Rheumatol Ther"},{"key":"2026011611152410000_12.1.e006503.8","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1237234","article-title":"Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis","volume":"14","author":"Wei","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026011611152410000_12.1.e006503.9","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-015-1023-4","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"16","author":"Kennedy-Martin","year":"2015","journal-title":"Trials"},{"key":"2026011611152410000_12.1.e006503.10","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/rheumatology\/kex394","article-title":"Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries","volume":"57","author":"Kilcher","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2026011611152410000_12.1.e006503.11","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/mr\/roab067","article-title":"Differences in patients\u2019 population and efficacy\/effectiveness of biologic disease-modifying antirheumatic drugs between randomized controlled trials and real-world settings in patients with rheumatoid arthritis - using the IORRA cohort","volume":"32","author":"Sugano","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2026011611152410000_12.1.e006503.12","doi-asserted-by":"crossref","unstructured":"Lanzillotta M , Boffini N , Barone E , et al . Safety of Janus Kinase Inhibitors: A Real-World Multicenter Retrospective Cohort Study. J Rheumatol 2023. doi:10.3899\/jrheum.2023-0145","DOI":"10.3899\/jrheum.2023-0145"},{"key":"2026011611152410000_12.1.e006503.13","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1007\/s12325-023-02619-6","article-title":"One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib","volume":"40","author":"Bergman","year":"2023","journal-title":"Adv Ther"},{"key":"2026011611152410000_12.1.e006503.14","doi-asserted-by":"crossref","first-page":"152314","DOI":"10.1016\/j.semarthrit.2023.152314","article-title":"Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study","volume":"64","author":"Scheepers","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2026011611152410000_12.1.e006503.15","first-page":"1763","article-title":"Real-world utilisation and switching between Janus kinase inhibitors in Australian patients with rheumatoid arthritis in the OPAL dataset","volume":"42","author":"Ciciriello","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"2026011611152410000_12.1.e006503.16","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/03009742.2024.2353433","article-title":"Retention rates of different Janus kinase inhibitors in rheumatoid arthritis: experience from a large monocentric cohort","volume":"53","author":"Farina","year":"2024","journal-title":"Scand J Rheumatol"},{"key":"2026011611152410000_12.1.e006503.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0306714","article-title":"Real-world comparative study of drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis","volume":"19","author":"Saito","year":"2024","journal-title":"PLoS ONE"},{"key":"2026011611152410000_12.1.e006503.18","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.3390\/jcm13164608","article-title":"Therapeutic Maintenance of Janus Kinase Inhibitors in Real Life for Rheumatoid Arthritis: Retrospective Study","volume":"13","author":"Farnos","year":"2024","journal-title":"JCM"},{"key":"2026011611152410000_12.1.e006503.19","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1093\/rheumatology\/kead543","article-title":"Correction to: Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study","volume":"63","author":"Hayashi","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026011611152410000_12.1.e006503.20","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3390\/jcm13061821","article-title":"Real-Life Comparison of Four JAK Inhibitors in Rheumatoid Arthritis (ELECTRA-i Study)","volume":"13","author":"Benucci","year":"2024","journal-title":"JCM"},{"key":"2026011611152410000_12.1.e006503.21","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s40744-025-00762-w","article-title":"Real-World Safety and Efficacy of Targeted Therapies in Rheumatoid Arthritis: A 5-Year, 5130-Case Follow-Up from FIRST Registry","volume":"12","author":"Sonomoto","year":"2025","journal-title":"Rheumatol Ther"},{"key":"2026011611152410000_12.1.e006503.22","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.70232","article-title":"Targeted Therapies for Rheumatoid Arthritis in Super-Elderly Society: Insights From FIRST Registry, Japan","volume":"28","author":"Sonomoto","year":"2025","journal-title":"Int J Rheum Dis"},{"key":"2026011611152410000_12.1.e006503.23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead075"},{"key":"2026011611152410000_12.1.e006503.24","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-004049","article-title":"CT informs detection and treatment options in rheumatoid arthritis complicated by pulmonary non-tuberculous mycobacterial disease from the FIRST registry","volume":"10","author":"Funada","year":"2024","journal-title":"RMD Open"},{"key":"2026011611152410000_12.1.e006503.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217344"},{"key":"2026011611152410000_12.1.e006503.26","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13123494","article-title":"The Retention Rate and Safety of JAK Inhibitors in Rheumatoid Arthritis: Real Word Data from a Monocentric Cohort","volume":"13","author":"Donzella","year":"2024","journal-title":"J Clin Med"},{"key":"2026011611152410000_12.1.e006503.27","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw341"},{"key":"2026011611152410000_12.1.e006503.28","doi-asserted-by":"crossref","first-page":"86","DOI":"10.55563\/clinexprheumatol\/g33ia5","article-title":"Difficult-to-treat rheumatoid arthritis with respect to responsiveness to biologic\/targeted synthetic DMARDs: a retrospective cohort study from the FIRST registry","volume":"40","author":"Ochi","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2026011611152410000_12.1.e006503.29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40744-022-00505-1","article-title":"Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases","volume":"10","author":"Salinas","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2026011611152410000_12.1.e006503.30","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/mr\/roaf017","article-title":"Three-year safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Final analysis of an all-case postmarketing surveillance study","volume":"35","author":"Kuwana","year":"2025","journal-title":"Mod Rheumatol"},{"key":"2026011611152410000_12.1.e006503.31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/mr\/roae064","article-title":"Safety of baricitinib in Japanese patients with rheumatoid arthritis in clinical use: 3-year data of all-case postmarketing surveillance study","volume":"35","author":"Okamoto","year":"2025","journal-title":"Mod Rheumatol"},{"key":"2026011611152410000_12.1.e006503.32","unstructured":"Xeljantz proper use information. 2024. Available: https:\/\/www.pfizerpro.jp\/medicine\/xeljanz\/files\/XEL51M011F_Vol15.pdf [Accessed 13 Jul 2025]."},{"key":"2026011611152410000_12.1.e006503.33","unstructured":"Pfizer shares co-primary endpoint results from post-marketing required safety study of xeljanz\u00ae (tofacitinib) in subjects with rheumatoid arthritis (ra). 2021."},{"key":"2026011611152410000_12.1.e006503.34","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/acr2.11602","article-title":"Changes in Patterns of Use of Advanced Therapies Following Emerging Data About Adverse Events in Patients With Rheumatoid Arthritis From the Veterans Affairs Health System","volume":"5","author":"Jeong","year":"2023","journal-title":"ACR Open Rheumatology"},{"key":"2026011611152410000_12.1.e006503.35","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.3390\/jcm13133929","article-title":"Influence of Safety Warnings on the Prescribing Attitude of JAK Inhibitors for Rheumatoid Arthritis in Italy","volume":"13","author":"Paroli","year":"2024","journal-title":"JCM"},{"key":"2026011611152410000_12.1.e006503.36","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/mr\/roaf007","article-title":"Real-world treatment persistence in csDMARD-IR and bDMARD-IR patients with rheumatoid arthritis in Japan: A large claims database study","volume":"35","author":"Takeuchi","year":"2025","journal-title":"Mod Rheumatol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-006503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T19:15:45Z","timestamp":1768590945000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-006503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,16]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/rmdopen-2025-006503"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-006503","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}